



Heart Rhythm Society
Restoring the Rhythm of Life

Title- Therapeutic Advancements in Atrial Fibrillation: New interventions and pharmacologic agents for optimizing outcomes

Program Overview

To inform electrophysiologists and other members of the cardiac care team about innovations in rhythm and rate control strategies for managing atrial fibrillation, including the use of novel multichannel antiarrhythmic agents for administration as monotherapy or as adjuncts to devices and surgical interventions to potentially elicit improved patient outcomes.



Heart Rhythm Society

Restoring the Rhythm of Life

Accreditation Statement

Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Heart Rhythm Society designates this education activity for a maximum of 2.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.



Heart Rhythm Society
Restoring the Rhythm of Life

Target Audience

This activity is intended for physicians, electrophysiologists, cardiologists, other members of the cardiac care team, and other healthcare professionals with an interest in antiarrhythmic therapies.



Heart Rhythm Society
Restoring the Rhythm of Life

Learning Objectives

Upon completion of this activity, participants should be able to:

- Identify the diagnostic and therapeutic challenges that are associated with managing atrial fibrillations and consequently contribute to its increasing prevalence.
- Describe the emerging interventions in the management of paroxysmal and persistent atrial fibrillation, including pharmacologic agents, devices for cardioversion and pacing, and surgical ablative techniques.
- Assess the electrophysiologic and pharmacologic profiles of both classic and novel multichannel antiarrhythmic drugs.
- Evaluate the clinical application of multichannel antiarrhythmic drugs in rhythm and rate control strategies for atrial fibrillation.



Heart Rhythm Society
Restoring the Rhythm of Life

Instructions for credit

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September, 2005 through September 2007.

1. Read the target audience, learning objectives and faculty disclosures
2. Study the educational activity.
3. Submit answers to the post-test questions and evaluation.

You must complete the post-test and respond to the evaluation questions to receive a certificate.



Heart Rhythm Society
Restoring the Rhythm of Life

Disclosures

Conflicts of Interest/Unlabeled/Unapproved Uses

The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. As a provider of continuing medical education, it is the Society's policy to ensure that the contents or formats of a continuing medical education (CME) activity are balanced, independent, objective, scientifically rigorous and free of commercial bias in all of its educational activities. It is the policy of HRS that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) or interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices.



Heart Rhythm Society

Restoring the Rhythm of Life

Faculty Disclosures

Camm, John A. has disclosed that he has received funding for research from British Heart Foundation, Pfizer Inc; Servier. He has also disclosed that he has served as a consultant with Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Bayer AG; Cardiome Pharma Corp.; C.V. Therapeutics, Inc.; GlaxoSmithKline; Guidant Corporation; Johnson & Johnson; Pfizer Inc; Procter & Gamble Pharmaceuticals; Sanofi-Synthelabo Inc.; Servier; St. Jude Medical, Inc.; Vitatron; Wyeth; Xention Discovery Ltd. He will be discussing the off-label, investigational or experimental drug- Dronedarone

Dorian, Paul; has disclosed that he has received research funding from AstraZeneca Pharmaceuticals LP; Cardiome Pharma Corp.; Procter & Gamble Pharmaceuticals; sanofi-aventis Group; Solvay S.A.; Wyeth. He also has disclosed that he serves as a consultant with AstraZeneca Pharmaceuticals LP; Cardiome Pharma Corp.; Procter & Gamble Pharmaceuticals; sanofi-aventis Group; Solvay S.A.. He will be discussing the off-label, investigational or experimental drugs Azimilide; dronedarone; dofetilide; RSD-1235, tedisamil



Heart Rhythm Society

Restoring the Rhythm of Life

Kowey, Peter R; has disclosed that he has received research funding from American Heart Association; Cardiome Pharma Corp.; GlaxoSmithKline; Guidant Corporation; Medtronic, Inc.; sanofi-aventis Group. He also disclosed that he serves as a consultant with AstraZeneca Pharmaceuticals LP; CardioNet; GlaxoSmithKline; Johnson & Johnson; Procter & Gamble Pharmaceuticals; Reliant Pharmaceuticals, Inc.; sanofi-aventis Group; Solvay S.A.; Wyeth. He has interests/stock ownership in CardioNet. He will be discussing the off-label, investigational, or experimental drug use of Azimilide, ATI-2042, AVE-0118, CVT-150, dronedarone, piboserod, RSD-1235, tedisamil, ZP-123

Ruskin, Jeremy N; has disclosed that he has received funding for research from Biosense Webster, Inc. He also serves as a consultant with CardioFocus Inc.; CryoCath Technologies, Inc.; Medtronic, Inc.; Pfizer Inc. He will not be discussing off-label, investigational or experimental drugs.

Waldo, Albert L; has disclosed that he has received funding for research from the National Institutes of Health/National Heart, Lung and Blood Institute, that he has served as a consultant with AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim GmbH; Cordis Webster, Inc.; CryoCor, Inc.; ev3 Inc.; Food and Drug Administration/Circulatory System Devices Panel of the Medical Devices Advisory Committee; GlaxoSmithKline; Sanofi-Aventis. He will not be discussing any off-label or investigational products.



Heart Rhythm Society

Restoring the Rhythm of Life

Disclaimer

The materials published on the website reflect the views of the authors, not those of the Heart Rhythm Society, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using therapies described in these materials.